Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Neuropharmacology. 2012 May 2;63(3):480–485. doi: 10.1016/j.neuropharm.2012.04.018

Fig. 1.

Fig. 1

Pregabalin modulates PPI differently across high and low gating groups. (A) Healthy human subjects (n = 7/PPI group) were treated with placebo, 50 and 200 mg Pregabalin (oral) in a counterbalanced cross-over design with 1 week washout. (B) C57Bl6J mice (n = 12/PPI group) were treated with 0, 30 and 100 mg/kg (IP) in a counterbalanced cross-over design with 1 week washout. High and low PPI groups were categorized by median split of placebo treatment. Data are depicted as mean +/− SEM percentage PPI. PPI is averaged over 30−120 ms ISIs in humans and 20−120 ms ISIs in mice. *p < 0.05, post-hoc simple contrasts after Group × Pregabalin interaction. See results for details.